Ascendis Pharma Collaborates with PANTHERx Rare
PANTHERx Rare, a prominent specialty pharmacy focused on rare diseases, has announced a significant partnership with Ascendis Pharma for the distribution of YORVIPATH, a groundbreaking treatment for hypoparathyroidism. This FDA-approved medication is a parathyroid hormone analog that aims to improve the quality of life for adults living with this rare condition.
Understanding Hypoparathyroidism
Hypoparathyroidism is a rare endocrine disorder that impacts approximately 70,000 individuals across the U.S. This condition arises from low levels of parathyroid hormone (PTH), which is crucial for regulating calcium and phosphorus levels in the body. Individuals diagnosed with hypoparathyroidism face significant health challenges due to the imbalance created by insufficient PTH. The most prevalent cause of this condition is damage to the parathyroid glands during neck surgery, accounting for 75% of cases. Genetic factors and conditions leading to the infiltration of the glands by various metals also contribute to its occurrence.
Symptoms and Complications
Patients experiencing chronic hypoparathyroidism may endure debilitating symptoms such as fatigue, muscle cramps, and tingling sensations in their extremities. More severe repercussions can include neuromuscular irritability, complications related to the kidneys, cognitive impairment, and extra-skeletal calcifications. The introduction of YORVIPATH provides a novel approach by ensuring continuous exposure to PTH over a 24-hour dosing schedule, thus mitigating these symptoms and enhancing overall patient health.
PANTHERx Rare: A Leader in Specialty Pharmacy
PANTHERx Rare is dedicated to optimizing patient access and support services, particularly in treating orphan diseases. The pharmacy aims to be a catalyst for change within the healthcare landscape, instituting programs that help patients get the medications they need efficiently. The dedication to supporting those with rare conditions is evident in their comprehensive approach to specialty medication distribution and patient care.
PANTHERx holds dual accreditations from the Accreditation Commission for Health Care (ACHC) and the Utilization Review Accreditation Commission (URAC) as a Rare Disease Center of Excellence. The pharmacy has also garnered accolades for patient satisfaction, including the MMIT Patient Choice Award, affirming their commitment to high-quality patient care and service efficiency.
The Future of Rare Disease Treatment
With more than 7,000 identified rare diseases and over 90% lacking an FDA-approved treatment, the pharmaceutical landscape for rare conditions is rapidly evolving. Recent advancements in drug approval processes and increasing awareness of orphan diseases have paved the way for hopeful developments for the rare disease community. As laws evolve and research advances, more effective treatments will continue becoming available, delivering unprecedented hope for those affected.
Connecting Patients with Care
As an essential resource for patients combating rare diseases, PANTHERx Rare emphasizes the importance of community connection and support. By collaborating with pharmaceutical companies like Ascendis Pharma, they strive to make treatments like YORVIPATH accessible to those who need them most. This partnership symbolizes a significant step forward in addressing the unmet needs of patients with hypoparathyroidism.
Frequently Asked Questions
What is YORVIPATH?
YORVIPATH is a FDA-approved parathyroid hormone analog indicated for treating hypoparathyroidism in adults, designed for continuous PTH exposure over 24 hours.
What is hypoparathyroidism?
Hypoparathyroidism is an endocrine disorder characterized by low levels of parathyroid hormone, leading to calcium and phosphorus imbalances in the body.
How does PANTHERx Rare support patients?
PANTHERx Rare provides access solutions and support services for patients with rare diseases, ensuring they receive necessary medications efficiently.
Why is continuous PTH exposure important?
Continuous exposure to PTH helps maintain balanced calcium levels and mitigates symptoms associated with hypoparathyroidism.
What are the common causes of hypoparathyroidism?
The most common cause is damage to the parathyroid glands during surgery, but it can also arise from genetic factors and gland infiltration.
